1 recruiting, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Withdrawn 1 |
Follow Exercise capacity VO2 maximum determination: new trials by email Literature Review of Exercise capacity VO2 maximum determination trials Research Report on Exercise capacity VO2 maximum determination
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors Empagliflozin Arm, Control Arm, Exercise capacity VO2 maximum determination - Obesity, Weight Loss | Phase 2 | Withdrawn | University of Alabama at Birmingham | 2025-01-30 | 2024-08-07 | |
| NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals Sacubitril, Valsartan 97-103 mg Oral Tablet, Valsartan 160 mg, Intravenous Glucose Tolerance Test - Diabetes Mellitus, Cardiovascular Diseases | Phase 2 | Recruiting | University of Alabama at Birmingham | 200 | 2020-08-15 | 2026-07-28 |
Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Insulin Resistance (1) · Metabolic Diseases (1) · Obesity (1) · Weight Loss (1)
University of Alabama at Birmingham (2)
United States (2)
PMID 25595796, PMID 27542885, PMID 28330649, PMID 31162140
R01HL163852 (1)